CRUSE ® —An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria
Clinical and Translational Allergy · 2024-01 · 14 (1)
DOI: 10.1002/clt2.12328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Allergy, online erschienen am 03.01.2024. Verfasst von Sophia Neisinger und 41 weiteren Autor:innen. Beteiligte Einrichtung: Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Unive…. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moxie, Celldex Therapeutics, UCARE (Urticaria Centers of Reference and Excellence).
Abstract (Originalsprache)
Background
Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user‐friendly platform to complete patient‐reported outcome measures (PROMs) on their mobile devices. CRUSE ® , the Chronic Urticaria Self Evaluation app, aims to address this unmet need.
Methods
CRUSE ® was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE ® app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real‐time insights. Additionally, CRUSE ® contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations.
Results
CRUSE ® was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country‐specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second‐generation antihistamines were used in 74.0% of days.
Conclusions
The initial data from CRUSE ® show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.
- Faculty of Medicine, MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, University of Porto, Porto, Portugal.
- CINTESIS-Center for Health Technology and Services Research, University of Porto, Porto, Portugal.
- RISE-Health Research Network, University of Porto, Porto, Portugal.
- Department of Dermatology, UCARE, Koç University School of Medicine, Istanbul, Turkey.
ORCID-Profile: Sophia Neisinger, Bernardo Sousa Pinto, Aiste Ramanauskaite, Jean Bousquet, Karsten Weller, Martin Metz, Markus Magerl, Emek Kocatürk, Ivan Cherrez-Ojeda, Ana M Gimenez-Arnau, Sabine Altrichter, Margarida Gonçalo, Simon Francis Thomsen, Jonny Peter, Zuotao Zhao, Marcus Maurer
Förderung
- Moxie
- Celldex Therapeutics
- UCARE (Urticaria Centers of Reference and Excellence)
- Novartis
Zitieren
APA
Neisinger, S., Sousa Pinto, B., Ramanauskaite, A., Bousquet, J., Weller, K., Metz, M., Magerl, M., Kocatürk, E., Cherrez-Ojeda, I., Gimenez-Arnau, A. M., Parisi, C. A. S., Altrichter, S., Ensina, L. F., Bouillet, L., Asero, R., Gonçalo, M., Guillet, C., Rutkowski, K., Bernstein, J. A., …, & Maurer, M. (2024). CRUSE ® —An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria. Clinical and Translational Allergy, 14(1). https://doi.org/10.1002/clt2.12328
Vancouver
Neisinger S, Sousa Pinto B, Ramanauskaite A, Bousquet J, Weller K, Metz M, et al. CRUSE ® —An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria. Clinical and Translational Allergy. 2024;14(1). doi:10.1002/clt2.12328
BibTeX
@article{Neisinger2024,
author = {Neisinger, Sophia and Sousa Pinto, Bernardo and Ramanauskaite, Aiste and Bousquet, Jean and Weller, Karsten and Metz, Martin and Magerl, Markus and Kocatürk, Emek and Cherrez-Ojeda, Ivan and Gimenez-Arnau, Ana M and Parisi, Claudio Alberto S and Altrichter, Sabine and Ensina, Luis Felipe and Bouillet, Laurence and Asero, Riccardo and Gonçalo, Margarida and Guillet, Carole and Rutkowski, Krzysztof and Bernstein, Jonathan A and Hardin, Hannah and Godse, Kiran and Brzoza, Zenon and Sousa, Jose Ignacio Larco and Thomsen, Simon Francis and van Doorn, Martijn and Hide, Michihiro and Ye, Young-Min and Vandersee, Staffan and Lapiņa, Lāsma and Peter, Jonny and Zhao, Zuotao and Han, Lianyi and Nasr, Iman and Rockmann-Helmbach, Heike and Sørensen, Jennifer Astrup and Kara, Rabia Öztaş and Kurjāne, Natalja and Kurchenko, Andrii I and Kaidashev, Igor and Tsaryk, Vladyslav and Stepanenko, Roman and Maurer, Marcus},
title = {CRUSE ® —An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria},
journal = {Clinical and Translational Allergy},
year = {2024},
volume = {14},
number = {1},
doi = {10.1002/clt2.12328}
}
EUVIMED